A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to- severe COPD and predominantly lower exacerbation risk.
|Number of pages||1|
|Publication status||Accepted/In press - 13 Sep 2021|
|Event||Eastern Pulmonary Conference 2021 - Palm Beach, UNITED STATES|
Duration: 30 Sep 2021 → 3 Oct 2021
|Conference||Eastern Pulmonary Conference 2021|
|Period||30/09/21 → 3/10/21|